Immunai Launches Free Access to Single-Cell Sequencing for Academic Researchers

• This program offers academic researchers free access to advanced single-cell RNA sequencing to accelerate discovery across cancer and autoimmunity.

• The initiative supports up to 1K samples per study, ensuring discoveries don’t stall due to funding.

Immunai, a leading AI biotech company specializing in mapping the human immune system, announced a new academic initiative to support human immunology research: the Immunai Grand Collaboration Initiative for Single-Cell Immune Profiling.

Through the program, academic researchers can apply for free access to Immunai’s single-cell sequencing platform, including full single-cell transcriptomic, surface proteomic, and TCR profiling, for studies involving up to 1,000 human samples. The company is accepting proposals from labs studying cancer, autoimmunity, or other immune-related areas, especially in patients treated with immunotherapy.

As cuts to the NIH and other agencies limit labs’ access to critical research infrastructure, Immunai is stepping up to help fill that gap. In doing so, Immunai is helping these teams continue uninterrupted even as traditional funding sources shrink.

“We want to support the kind of research that too often gets paused for budget reasons,” said Noam Solomon, PhD, CEO and Co-Founder of Immunai. “Through broader availability of these single-cell immune profiling, Immunai hopes to help these labs uncover novel pathways in immunology and actionable translational and clinical insights, and make real progress, even when traditional funding falls short.”

Selected projects will receive:

• Free single-cell RNA sequencing for 100–1,000 patient samples (PBMC or tissue)
• Multi-omic data including CITE-seq (~1,500 genes per cell and 80+ surface proteins), and TCR sequencing
• Raw data, QC and annotations returned to researchers for their own analysis and publications
• Inclusion in AMICA™, Immunai’s reference immune atlas, to help fuel broader discovery

This initiative is open to investigators conducting non-commercial human studies, particularly those involving patients who have received immunotherapy-based treatment regimens. All samples must include relevant clinical metadata and proper regulatory approval for data sharing.

Immunai’s mission is to map the immune system and to unlock its full therapeutic potential. By opening access to powerful single-cell technologies, Immunai hopes to help scientific teams uncover meaningful patterns in immunity and insights that are critical for identifying new drug targets, understanding resistance mechanisms, and improving patient treatment outcomes.

Applications are due by October 1, 2025. Sample processing will begin in Q4 2025 through early 2026.

Proposals will be evaluated by an expert review panel that includes the following leaders in immunology, genomics, and drug development:

• Dr. Stanley R. Frankel, MD, adjunct Professor of Medicine at the Division of Hematology/Oncology at Columbia University’s Vagelos College of Physicians and Surgeons
• Dr. Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President, Worldwide Research, Development, and Medical at Pfizer
• Dr. Ansuman Satpathy, MD, PhD, Physician-Scientist, Biotech Founder/Investor, Associate Professor of Pathology and Immunology at Stanford University.
  
  
• Professor Adeeb Rahman, Chief Technology Officer at Immunai

Researchers interested are invited to apply via the online application form.

About Immunai
Immunai is developing an AI model of the immune system, the IDE™ engine, leveraging its large proprietary clinically annotated single-cell multi-omics immunology knowledgebase AMICA™ and advanced artificial intelligence and machine learning, in order to discover and improve the development of novel immune modulating therapeutics. With a team of over 170 experts, the company collaborates with leading pharmaceutical firms and academic institutions. Immunai is headquartered in New York City and has raised close to $270 million in funding to date. Find out more at immunai.com and follow us on LinkedIn and X.

Contact Information

Jennifer Henry

PR for Immunai

VSC for Immunai

Contact via E-mail